Lipid bulk and cardiac imaging cannot identify which patients have rupture-prone plaque with thin fibrous caps. Therefore, finding serologic markers with high specificity for advanced plaque is a useful diagnostic tool in cardiovascular risk stratification. The Lp-PLA2 test helps physicians to identify patients who would good turn from more aggressive therapy and is especially recommended for intermediate and high-risk patients.

Once thought to be a simple process caused by the deposition of too much cholesterol in the arteries, atherosclerosis it being so that appears to be a condition in which place the arterial lesions are inflamed, eventually leading to plaque rupture causing a heart attack or stroke. Lp-PLA2 is associated with a doubling of cardiovascular risk.

“What makes Lp-PLA2 so unique is that it is extremely characteristic to vascular inflammation, making it an excellent indicator of sedulous atherosclerosis, that is otherwise difficult to detect from one side conventional methods,” states Dr. Jan Troup, Ph.D., Director of Lipid Science at SpectraCell. “It tells a doctor that the risk of MI or stroke is higher what is due to developing vulnerable plaque. Doctors be able to use this information to modify treatment strategies determined by lipoprotein particles alone.”

Since stroke is the leading cause of disability and third leading cause of death in America, early detection and prevention is key, especially since 68% of heart attacks and strokes occur from blood clots, not narrowing of the arteries.

Although Lp-PLA2 is any inflammatory marker, it is not affected by inflammation that might come to one’s mind from infection or injury. This makes Lp-PLA2 a to a greater degree specific marker than the further familiar CRP (C-Reactive Protein) which can be elevated from systemic infection, even when the vascular walls are healthy. High Lp-PLA2 in combination with heaven-kissing hs-CRP increases the risk level four fold.

Since 50% of total heart attacks occur in patients with normal cholesterol values, the Lp-PLA2 test is oftentimes used in conjunction with advanced lipoprotein tests. SpectraCell’s LPP+(TM) combines advanced cholesterol testing with additional exempt from arbitrary control risk factors such similar to Lp-PLA2, hs-CRP, insulin and homocysteine. It is typically covered by the agency of colors insurance and Medicare.

About SpectraCell Laboratories — SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing with the patent pending LPP(TM) (Lipoprotein Particle Profile) and FIA(TM) (Functional Intracellular Analysis) and tests.

SpectraCell’s LPP(TM) testing is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell’s LPP(TM) directly measures the number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.

SpectraCell’s FIA(TM) testing is an innovative impost of a patient’s nutritional status. Unlike traditional serum, hair and urine tests, SpectraCell’s FIA(TM) measures how an personal’s frosty blood cells function in specific nutritional environments. Over 30 vitamins, minerals, amino acids and antioxidants are evaluated. As a fruit, individual differences in metabolism, age, genetics, soundness, prescription drug usage, absorption rate and other factors are taken into consideration.

??? ???? ??????? ?? ????????? ??????

Мой блог находят по следующим фразам